PointState Capital’s bluebird bio BLUE Stock Holding History

PointState Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-818	Closed	-$930K	–	72
2019 Q4	$930K	Buy	+818	New	+$889K	0.02%	104
2019 Q2	–	Sell	-317	Closed	-$645K	–	115
2019 Q1	$645K	Buy	+317	New	+$558K	0.01%	118
2017 Q2	–	Sell	-12,998	Closed	-$15.3M	–	140
2017 Q1	$15.3M	Buy	+12,998	New	+$13.3M	0.16%	85
2015 Q1	–	Sell	-5,790	Closed	-$6.88M	–	123
2014 Q4	$6.88M	Sell	5,790 -4,246	-42%	-$2.84M	0.12%	89
2014 Q3	$4.66M	Sell	10,036 -11,194	-53%	-$5.17M	0.08%	74
2014 Q2	$10.6M	Buy	+21,230	New	+$6.81M	0.13%	75
2014 Q1	–	Sell	-7,720	Closed	-$2.1M	–	122
2013 Q4	$2.1M	Sell	7,720 -7,720	-50%	-$2.16M	0.03%	135
2013 Q3	$5.39M	Buy	+15,440	New	+$5.73M	0.09%	102

Other funds holding BLUE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PointState Capital's BLUE Position: Q1 2020 in Review

PointState Capital sold out of bluebird bio (BLUE) in Q1 2020, closing a stake of 818 shares — an estimated $930K sold.

PointState Capital first reported a position in BLUE in Q3 2013 and held it in 8 quarters. The position peaked at $15.3M in Q1 2017. 247 funds tracked by Wall St. Rank hold BLUE as of Q1 2020.

PointState Capital reported no remaining bluebird bio position as of Q1 2020 after selling out during the quarter.
PointState Capital sold 818 bluebird bio shares in Q1 2020, an estimated $930K.
PointState Capital first reported a position in bluebird bio in Q3 2013 and held it in 8 quarters.
PointState Capital's bluebird bio position peaked at $15.3M in Q1 2017.
247 funds tracked by Wall St. Rank held bluebird bio as of Q1 2020.

Based on PointState Capital's 13F filing for Q1 2020, filed 15 May 2020.